SlideShare a Scribd company logo
Presented By Facilitated By
ALBIN JOSE.V DR. SHIVALINGE GOWDA K.P.
M.Pharm- I H.O.D & Associate Professor
Dept.Of Pharmacology Dept.Of Pharmacology
PESCP PESCP
4/16/20151
EVALUATION SEMINAR ON
MOLECULAR MECHANISMS OF FDA APPROVED
DRUGS IN 2014
FDA APPROVED DRUGS IN 2014
4/16/20152
1. Dyloject - Diclofenac sodium Injection
2.Namzaric - Donepezil and memantine
3.Saxenda - Liraglutide Injection
4.Opdivo - Nivolumab Injection
5.Rapivab - Peramivir Injection
6.Zerbaxa - Ceftolozane and tazobactam Injection
7.Lynparza - Olaparib Capsules
8.Viekira Pak - Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir Tablets
9.Xtoro -Finafloxacin Otic Suspension
10.Signifor LAR - Pasireotide for Injectable Suspension
4/16/20153
11.Gardasil 9 - Human papillomavirus 9-valent vaccine,
recombinant Injection
12.Blincyto - Blinatumomab Injection
13.Kitabis Pak - Tobramycin Inhalation Solution
14.Onexton - Benzoyl peroxide and clindamycin phosphate
Gel
15.Hysingla ER - Hydrocodone bitartrate Extended-Release
Tablets
16.Lemtrada - Alemtuzumab Injection
17.Xigduo XR - Dapagliflozin and metformin hydrochloride
Extended-Release Tablets
18.Trumenba - Meningococcal group B vaccine
19.Obizur -Antihemophilic factor (recombinant)
4/16/20154
1. Dyloject -Diclofenac sodium Injection
Company: Javelin Pharmaceuticals, Inc.
Approved indication: Pain
Diclofenac sodium injection
 It is an intravenous non-steroidal anti-inflammatory drug (NSAID)
for the management of acute moderate-to-severe pain in adults.
Molecular Mechanism
1. Inhibition of prostaglandin synthesis by inhibition
of cyclooxygenase (COX)
4/16/20155
2. Namzaric -Donepezil and Memantine
Company: Actavis plc and Adamas Pharmaceuticals Inc.
Approved indication : Alzheimer's Disease
Molecular Mechanism
1. Memantine hydrochloride - NMDA receptor antagonist
2. Donepezil hydrochloride -acetylcholinesterase inhibitor.
3. Saxenda -Liraglutide Injection
Company: Novo Nordisk Inc.
Approved indication : Obesity
Liraglutide is a once-daily dose
 Glucagon- peptide-1 (GLP-1) analogue for the treatment of
obesity.
4/16/20156
4. Opdivo - Nivolumab Injection
Company: Bristol-Myers Squibb Company
Approved indication: Melanoma – Metastatic
 Nivolumab is a programmed death receptor-1 (PD-1) blocking
antibody for the treatment of advanced melanoma.
Molecular mechanism
 Human IgG4 PD-1 immune checkpoint inhibitor “Nivolumab for
treatment of malignant melanoma.
5. Rapivab -Peramivir Injection
Company: BioCryst Pharmaceuticals, Inc.
Approved indication: Influenza
 Peramivir is an influenza virus neuraminidase inhibitor
 Indicated for the treatment of acute uncomplicated influenza in
adults.
4/16/20157
Mechanism of Action:
 Peramivir is a cyclopentane analogue
 It competitively binds to the active site of the influenza virus neuraminidase.
 Peramivir inhibits the neuraminidase activity of several strains of influenza A and
B viruses, including H1N1 influenza A (swine influenza).
6. Zebra -Ceftolozane and Tazobactam Injection
Company: Cubist Pharmaceuticals, Inc.
Approved indication: Intraabdominal Infection, Urinary Tract Infection
 Ceftolozane and Tazobactam is a cephalosporin and beta-lactamase inhibitor
combination for the treatment of complicated intra-abdominal infections (cIAI)
and complicated urinary tract infections (cUTI).
Molecular mechanism
 Ceftolozane-Inhibit the cell wall synthesis.
 Tazobactum-Beta-lactamase inhibitor.
4/16/20158
7.Lynparza-Olaparib Capsules
Company: AstraZeneca
Approved indication: Ovarian Cancer
Mechanism of Action:
 Poly adenosine 5’-diphospho ribose polymerase (PARP)
family inhibitor PARP-1 PARP- 2 PARP-3.
8. Viekira Pak -Ombitasvir/Paritaprevir/Ritonavir with
Dasabuvir Tablets
Company: AbbVie Inc.
Approved indication: Chronic Hepatitis C
 Viekira Pak for the treatment of patients with genotype 1
chronic hepatitis C virus (HCV) infection.
4/16/20159
Mechanism of action
Ombitasvir - NS5A inhibitor with potent pangenotypic picomolar antiviral
activity
Paritaprevir - Inhibitor of the NS3/4A serine protease
Ritonavir – Potent inhibitor of CYP3A4 enzymes
Dasabuvir - Nonnucleoside NS5B polymerase inhibitor and also used for
pharmacologic booster paritaprevir
9. Soolantra -Ivermectin Cream
Company: Galderma Laboratories, L.P.
Approved indication: Acne Rosacea
 Lvermectin is a topical antiparasitic with anti-inflammatory properties for the
treatment of rosacea potentially caused by the microscopic skin
mite Demodex folliculorum.
Molecular mechanism
 Anthelmintic drug- Inhibiting neuronal activity and muscular contractility in
arthropods and nematodes
 By activating glutamate-gated chloride channels (GluClRs) at nanomolar
concentrations
4/16/201510
10.Xtoro -Finafloxacin Otic Suspension
Company: Alcon Laboratories, Inc.
Approved indication : Otitis Externa
Finafloxacin Otic suspension is a fluoroquinolone
antimicrobial for the treatment of acute otitis externa,
commonly known as swimmer’s ear.
Molecular mechanism
Quinolones-Inhibit the enzyme bacterial DNA gyrase.
11.Signifor LAR -Pasireotide for Injectable Suspension
Company: Novartis
Approved indication: Acromegaly
Pasireotide is a long acting a somatostatin analog
formulation for the treatment of patients with acromegaly.
4/16/201511
Molecular mechanism
1. Pasireotide activates somatostatin receptors,
exhibiting a much higher binding affinity for
Somatostatin receptors 1, 3, and 5 than octreotide in
vitro, as well as a comparable binding
affinity for somatostatin receptor
2. The binding and activation of the somatostatin
receptors causes inhibition of ACTH secretion
and results in reduced cortisol secretion in
Cushing's disease patients. Also this agent is more
potent than somatostatin in inhibiting the release of
human growth hormone (HGH),
glucagon, and insulin.
12.Gardasil 9 -Human papillomavirus 9-valent vaccine,
recombinant Injection
Company: Merck & Co., Inc.
Approved indication: Human Papillomavirus Prophylaxis
Human papillomavirus 9-valent vaccine, recombinant) is a 9-valent HPV
vaccine for the prevention of cervical, vulvar, vaginal, and anal cancers
caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.
13.Blincyto -Blinatumomab Injection
Company: Amgen Inc.
Approved indication: Acute Lymphoblastic Leukemia
Blinatumomab is a bispecific CD19-directed CD3 T-cell engager
indicated for the treatment of Philadelphia chromosome-negative
relapsed or refractory B-cell precursor acute lymphoblastic leukemia
(ALL). 4/16/201512
4/16/201513
Molecular mechanism
 A molecule of Blinatumomab combines two binding sites:
 CD3 site for T cells and CD19 site for the target B cells.
 CD3 is part of the T cell receptor.
 The drug works by linking these two cell types
activating the T cell to exert cytotoxic activity on the target cell.
14.Kitabis Pak -Tobramycin Inhalation Solution
Company: PulmoFlow, Inc.
Approved indication: Cystic Fibrosis
Tobramycin is an aminoglycoside inhalation solution co-
packaged with a PARI LC PLUS® Reusable Nebulizer for the
management of cystic fibrosis.
4/16/201514
Molecular mechanism
Tobramycin binding to a site on the
bacterial 30S and 50S ribosome,
preventing formation of the 70S complex.
As a result, mRNA cannot be translated into protein and
cell death .
15.Onexton-Benzoyl peroxide and Clindamycin
phosphate Gel
Company: Valeant Pharmaceuticals International,
Inc.
Approved indication: Acne
Benzoyl peroxide and Clindamycin phosphate is an
antimicrobial and lincosamide antibacterial combination
for the once-daily topical treatment of acne vulgaris
4/16/201515
Molecular mechanism
Clindamycin: It is a lincosamide antibacterial.
Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent
with bacteriocidal and keratolytic effects, but the precise
mechanism of action is unknown.
16.Hysingla ER-Hydrocodone bitartrate Extended-
Release Tablets
Company: Purdue Pharma L.P.
Approved indication: Chronic Pain
Hydrocodone is a single-entity (without acetaminophen)
extended-release opioid analgesic for around-the-clock
management of moderate to severe chronic pain.
4/16/201516
Molecular mechanism
 As a narcotic, Hydrocodone relieves pain by binding to Opioid receptors in
the CNS.
 It acts primarily on μ-opioid receptors, with about six times lesser affinity to
δ-opioid receptors.
 In blood, 20–50% of hydrocodone is bound to protein.
17.Lemtrada-Alemtuzumab Injection
Company: Genzyme
Approved indication: Multiple Sclerosis
 Alemtuzumab is a CD52-directed cytolytic monoclonal antibody indicated for
the treatment of relapsing forms of multiple sclerosis (MS).
Molecular mechanism
 Alemtuzumab is a humanized mAb, which targets the surface molecule
CD52 on all T cell populations and other cellular components of the
immune system such as thymocytes, B cells, and monocytes.
 Alemtuzumab, which is administered intravenously, depletes T as well as B
lymphocyte populations for extended periods.
Adverse effects in MS patients such as thyroid disorders and
idiopathic thrombocytopenic purpura.
4/16/201517
18.Xigduo XR -Dapagliflozin and Metformin
hydrochloride Extended-Release Tablets
Company: AstraZeneca
Approved indication: Diabetes Type 2
 Xigduo XR (Dapagliflozin and Metformin
hydrochloride)
 It is a once-daily sodium-glucose cotransporter 2
(SGLT2) inhibitor and biguanide combination for the
treatment of type 2 diabetes.
4/16/201518
Molecular mechanism
Dapagliflozin –
 Inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2)
 which are responsible for at least 90% of the
glucose reabsorption in the kidney.
 Blocking this transporter mechanism causes blood glucose to be
eliminated through the urine.
Metformin
 Metformin decreases hyperglycemia primarily by suppressing
glucose production by the liver (hepatic gluconeogenesis).
19.Trumenba -meningococcal group B vaccine
Company: Pfizer Inc.
Approved indication: Meningococcal Meningitis Prophylaxis
 Trumenba (Meningococcal group B vaccine) is indicated for active
immunization to prevent invasive disease caused by Neisseria
meningitidis serogroup B in adolescents and young adults.
MOLECULAR MECHANISMS OF FDA APPROVED DRUGS IN 2014

More Related Content

What's hot

Presentation on antiviral agent’s
Presentation on antiviral agent’sPresentation on antiviral agent’s
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
Jegan Nadar
 
Antiviral 1
Antiviral 1Antiviral 1
Antiviral 1
Bruno Mmassy
 
Antiviral Drugs
Antiviral DrugsAntiviral Drugs
Antiviral Drugs
Sameh Abdel-ghany
 
Anti viral drugs presentation
Anti viral drugs presentation Anti viral drugs presentation
Anti viral drugs presentation
Abdi Qani Yuusuf
 
Antiviral agents-medicinal chemistry
Antiviral agents-medicinal chemistryAntiviral agents-medicinal chemistry
Antiviral agents-medicinal chemistry
NIKITHAJ8
 
Zidovudine
ZidovudineZidovudine
Zidovudine
Chinmay Maheshwari
 
Antifungal and Antiviral Agents
Antifungal and Antiviral AgentsAntifungal and Antiviral Agents
Antifungal and Antiviral Agents
A. Rakha
 
Anti viral drugs of medicinal chemistry
Anti viral drugs of medicinal chemistryAnti viral drugs of medicinal chemistry
Anti viral drugs of medicinal chemistry
Pranjal Saxena
 
Class antiviral drugs 2
Class antiviral drugs 2Class antiviral drugs 2
Class antiviral drugs 2
Raghu Prasada
 
Antiviral agents
Antiviral agentsAntiviral agents
Antiviral agents
Gideon Mutai
 
Antiviral
AntiviralAntiviral
Antiviral
FarazaJaved
 
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
Shubhendu Kumar Dash
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibiotics
Areej Abu Hanieh
 
Class macrolides
Class macrolides Class macrolides
Class macrolides
Raghu Prasada
 
Anti viral agents
Anti viral agentsAnti viral agents
Anti viral agents
raj kumar
 
Anti viral agents ppt
Anti viral agents pptAnti viral agents ppt
Anti viral agents ppt
Navdha Soni
 
CHEMOTHERAPY MCQS PDF
CHEMOTHERAPY MCQS PDFCHEMOTHERAPY MCQS PDF
CHEMOTHERAPY MCQS PDF
MINANI Theobald
 
Antiviral chemotherapy
Antiviral chemotherapyAntiviral chemotherapy
Antiviral chemotherapy
Bruno Mmassy
 

What's hot (19)

Presentation on antiviral agent’s
Presentation on antiviral agent’sPresentation on antiviral agent’s
Presentation on antiviral agent’s
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
 
Antiviral 1
Antiviral 1Antiviral 1
Antiviral 1
 
Antiviral Drugs
Antiviral DrugsAntiviral Drugs
Antiviral Drugs
 
Anti viral drugs presentation
Anti viral drugs presentation Anti viral drugs presentation
Anti viral drugs presentation
 
Antiviral agents-medicinal chemistry
Antiviral agents-medicinal chemistryAntiviral agents-medicinal chemistry
Antiviral agents-medicinal chemistry
 
Zidovudine
ZidovudineZidovudine
Zidovudine
 
Antifungal and Antiviral Agents
Antifungal and Antiviral AgentsAntifungal and Antiviral Agents
Antifungal and Antiviral Agents
 
Anti viral drugs of medicinal chemistry
Anti viral drugs of medicinal chemistryAnti viral drugs of medicinal chemistry
Anti viral drugs of medicinal chemistry
 
Class antiviral drugs 2
Class antiviral drugs 2Class antiviral drugs 2
Class antiviral drugs 2
 
Antiviral agents
Antiviral agentsAntiviral agents
Antiviral agents
 
Antiviral
AntiviralAntiviral
Antiviral
 
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
Punica granatum rind extracts- a viable therapeutic option for Covid-19 ?
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibiotics
 
Class macrolides
Class macrolides Class macrolides
Class macrolides
 
Anti viral agents
Anti viral agentsAnti viral agents
Anti viral agents
 
Anti viral agents ppt
Anti viral agents pptAnti viral agents ppt
Anti viral agents ppt
 
CHEMOTHERAPY MCQS PDF
CHEMOTHERAPY MCQS PDFCHEMOTHERAPY MCQS PDF
CHEMOTHERAPY MCQS PDF
 
Antiviral chemotherapy
Antiviral chemotherapyAntiviral chemotherapy
Antiviral chemotherapy
 

Similar to MOLECULAR MECHANISMS OF FDA APPROVED DRUGS IN 2014

Immunomodulators in Ophthalmology
Immunomodulators in OphthalmologyImmunomodulators in Ophthalmology
Immunomodulators in Ophthalmology
saanvi2011
 
Cancer nanotechnology
Cancer nanotechnologyCancer nanotechnology
Cancer nanotechnology
seyed mohammad motevalli
 
Antisense Oligonucleotides
Antisense OligonucleotidesAntisense Oligonucleotides
Antisense Oligonucleotides
Sanchit Dhankhar
 
Novel antibiotics
Novel antibioticsNovel antibiotics
Novel antibiotics
HimikaRathi
 
Chemotherapy of maleria
Chemotherapy of maleriaChemotherapy of maleria
Chemotherapy of maleria
FarazaJaved
 
Malaria vaccines cum antimalaria drugs, by bdollar
Malaria vaccines cum antimalaria drugs, by bdollarMalaria vaccines cum antimalaria drugs, by bdollar
Malaria vaccines cum antimalaria drugs, by bdollar
bernard bahaah
 
Antiviral chemotherapy
Antiviral chemotherapyAntiviral chemotherapy
Antiviral chemotherapy
Bruno Mmassy
 
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium TuberculosisNew agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
Areej Abu Hanieh
 
Paxlovid and Molnupiravir What Are The Differences.pdf
Paxlovid and Molnupiravir What Are The Differences.pdfPaxlovid and Molnupiravir What Are The Differences.pdf
Paxlovid and Molnupiravir What Are The Differences.pdf
DoriaFang
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
Dr Resu Neha Reddy
 
Antisense therapy
Antisense therapyAntisense therapy
Antisense therapy
pooranachithra flowry
 
Anti fungal drugs (Antibiotics)
Anti fungal drugs (Antibiotics)Anti fungal drugs (Antibiotics)
Anti fungal drugs (Antibiotics)
ManoharReddy183
 
Leprosy
LeprosyLeprosy
Leprosy
Vijay Kumar
 
Leprosy BY VIJAY
Leprosy BY VIJAYLeprosy BY VIJAY
Leprosy BY VIJAY
Vijay Kumar
 
Leprosy 120909082328-phpapp02
Leprosy 120909082328-phpapp02Leprosy 120909082328-phpapp02
Leprosy 120909082328-phpapp02
Vijay Kumar
 
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
Ravi Kant Agrawal
 
Chloramphenicol.pptx
Chloramphenicol.pptxChloramphenicol.pptx
Chloramphenicol.pptx
PrajwalGhatol1
 
7 antimicrobial theapy
7 antimicrobial theapy7 antimicrobial theapy
7 antimicrobial theapy
Ephrem Tamiru
 
mondalanti-viral_drugs_f09.pdf
mondalanti-viral_drugs_f09.pdfmondalanti-viral_drugs_f09.pdf
mondalanti-viral_drugs_f09.pdf
MehreenFarooq3
 
Chemotherapy of tuberculosis
Chemotherapy of tuberculosisChemotherapy of tuberculosis
Chemotherapy of tuberculosis
pctebpharm
 

Similar to MOLECULAR MECHANISMS OF FDA APPROVED DRUGS IN 2014 (20)

Immunomodulators in Ophthalmology
Immunomodulators in OphthalmologyImmunomodulators in Ophthalmology
Immunomodulators in Ophthalmology
 
Cancer nanotechnology
Cancer nanotechnologyCancer nanotechnology
Cancer nanotechnology
 
Antisense Oligonucleotides
Antisense OligonucleotidesAntisense Oligonucleotides
Antisense Oligonucleotides
 
Novel antibiotics
Novel antibioticsNovel antibiotics
Novel antibiotics
 
Chemotherapy of maleria
Chemotherapy of maleriaChemotherapy of maleria
Chemotherapy of maleria
 
Malaria vaccines cum antimalaria drugs, by bdollar
Malaria vaccines cum antimalaria drugs, by bdollarMalaria vaccines cum antimalaria drugs, by bdollar
Malaria vaccines cum antimalaria drugs, by bdollar
 
Antiviral chemotherapy
Antiviral chemotherapyAntiviral chemotherapy
Antiviral chemotherapy
 
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium TuberculosisNew agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
 
Paxlovid and Molnupiravir What Are The Differences.pdf
Paxlovid and Molnupiravir What Are The Differences.pdfPaxlovid and Molnupiravir What Are The Differences.pdf
Paxlovid and Molnupiravir What Are The Differences.pdf
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
 
Antisense therapy
Antisense therapyAntisense therapy
Antisense therapy
 
Anti fungal drugs (Antibiotics)
Anti fungal drugs (Antibiotics)Anti fungal drugs (Antibiotics)
Anti fungal drugs (Antibiotics)
 
Leprosy
LeprosyLeprosy
Leprosy
 
Leprosy BY VIJAY
Leprosy BY VIJAYLeprosy BY VIJAY
Leprosy BY VIJAY
 
Leprosy 120909082328-phpapp02
Leprosy 120909082328-phpapp02Leprosy 120909082328-phpapp02
Leprosy 120909082328-phpapp02
 
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
Antibiotics inhibiting protein synthesis 4 lincosamides, streptogramins and o...
 
Chloramphenicol.pptx
Chloramphenicol.pptxChloramphenicol.pptx
Chloramphenicol.pptx
 
7 antimicrobial theapy
7 antimicrobial theapy7 antimicrobial theapy
7 antimicrobial theapy
 
mondalanti-viral_drugs_f09.pdf
mondalanti-viral_drugs_f09.pdfmondalanti-viral_drugs_f09.pdf
mondalanti-viral_drugs_f09.pdf
 
Chemotherapy of tuberculosis
Chemotherapy of tuberculosisChemotherapy of tuberculosis
Chemotherapy of tuberculosis
 

Recently uploaded

Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Dutch Power
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Dutch Power
 
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
OECD Directorate for Financial and Enterprise Affairs
 
Carrer goals.pptx and their importance in real life
Carrer goals.pptx  and their importance in real lifeCarrer goals.pptx  and their importance in real life
Carrer goals.pptx and their importance in real life
artemacademy2
 
ASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdfASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdf
ToshihiroIto4
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
gharris9
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
amekonnen
 
2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
Frederic Leger
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
samililja
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
Faculty of Medicine And Health Sciences
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Rosie Wells
 
Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
kkirkland2
 
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
SkillCertProExams
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
OECD Directorate for Financial and Enterprise Affairs
 
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPointMẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
1990 Media
 
Media as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern EraMedia as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern Era
faizulhassanfaiz1670
 
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdfSupercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Access Innovations, Inc.
 
Gregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptxGregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptx
gharris9
 

Recently uploaded (19)

Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
 
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
 
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
 
Carrer goals.pptx and their importance in real life
Carrer goals.pptx  and their importance in real lifeCarrer goals.pptx  and their importance in real life
Carrer goals.pptx and their importance in real life
 
ASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdfASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdf
 
Gregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics PresentationGregory Harris - Cycle 2 - Civics Presentation
Gregory Harris - Cycle 2 - Civics Presentation
 
Tom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issueTom tresser burning issue.pptx My Burning issue
Tom tresser burning issue.pptx My Burning issue
 
2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf2024-05-30_meetup_devops_aix-marseille.pdf
2024-05-30_meetup_devops_aix-marseille.pdf
 
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
 
XP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to LeadershipXP 2024 presentation: A New Look to Leadership
XP 2024 presentation: A New Look to Leadership
 
Updated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidismUpdated diagnosis. Cause and treatment of hypothyroidism
Updated diagnosis. Cause and treatment of hypothyroidism
 
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsCollapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
 
Burning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdfBurning Issue Presentation By Kenmaryon.pdf
Burning Issue Presentation By Kenmaryon.pdf
 
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
 
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
 
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPointMẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
Mẫu PPT kế hoạch làm việc sáng tạo cho nửa cuối năm PowerPoint
 
Media as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern EraMedia as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern Era
 
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdfSupercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
 
Gregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptxGregory Harris' Civics Presentation.pptx
Gregory Harris' Civics Presentation.pptx
 

MOLECULAR MECHANISMS OF FDA APPROVED DRUGS IN 2014

  • 1. Presented By Facilitated By ALBIN JOSE.V DR. SHIVALINGE GOWDA K.P. M.Pharm- I H.O.D & Associate Professor Dept.Of Pharmacology Dept.Of Pharmacology PESCP PESCP 4/16/20151 EVALUATION SEMINAR ON MOLECULAR MECHANISMS OF FDA APPROVED DRUGS IN 2014
  • 2. FDA APPROVED DRUGS IN 2014 4/16/20152 1. Dyloject - Diclofenac sodium Injection 2.Namzaric - Donepezil and memantine 3.Saxenda - Liraglutide Injection 4.Opdivo - Nivolumab Injection 5.Rapivab - Peramivir Injection 6.Zerbaxa - Ceftolozane and tazobactam Injection 7.Lynparza - Olaparib Capsules 8.Viekira Pak - Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir Tablets 9.Xtoro -Finafloxacin Otic Suspension 10.Signifor LAR - Pasireotide for Injectable Suspension
  • 3. 4/16/20153 11.Gardasil 9 - Human papillomavirus 9-valent vaccine, recombinant Injection 12.Blincyto - Blinatumomab Injection 13.Kitabis Pak - Tobramycin Inhalation Solution 14.Onexton - Benzoyl peroxide and clindamycin phosphate Gel 15.Hysingla ER - Hydrocodone bitartrate Extended-Release Tablets 16.Lemtrada - Alemtuzumab Injection 17.Xigduo XR - Dapagliflozin and metformin hydrochloride Extended-Release Tablets 18.Trumenba - Meningococcal group B vaccine 19.Obizur -Antihemophilic factor (recombinant)
  • 4. 4/16/20154 1. Dyloject -Diclofenac sodium Injection Company: Javelin Pharmaceuticals, Inc. Approved indication: Pain Diclofenac sodium injection  It is an intravenous non-steroidal anti-inflammatory drug (NSAID) for the management of acute moderate-to-severe pain in adults. Molecular Mechanism 1. Inhibition of prostaglandin synthesis by inhibition of cyclooxygenase (COX)
  • 5. 4/16/20155 2. Namzaric -Donepezil and Memantine Company: Actavis plc and Adamas Pharmaceuticals Inc. Approved indication : Alzheimer's Disease Molecular Mechanism 1. Memantine hydrochloride - NMDA receptor antagonist 2. Donepezil hydrochloride -acetylcholinesterase inhibitor. 3. Saxenda -Liraglutide Injection Company: Novo Nordisk Inc. Approved indication : Obesity Liraglutide is a once-daily dose  Glucagon- peptide-1 (GLP-1) analogue for the treatment of obesity.
  • 6. 4/16/20156 4. Opdivo - Nivolumab Injection Company: Bristol-Myers Squibb Company Approved indication: Melanoma – Metastatic  Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of advanced melanoma. Molecular mechanism  Human IgG4 PD-1 immune checkpoint inhibitor “Nivolumab for treatment of malignant melanoma. 5. Rapivab -Peramivir Injection Company: BioCryst Pharmaceuticals, Inc. Approved indication: Influenza  Peramivir is an influenza virus neuraminidase inhibitor  Indicated for the treatment of acute uncomplicated influenza in adults.
  • 7. 4/16/20157 Mechanism of Action:  Peramivir is a cyclopentane analogue  It competitively binds to the active site of the influenza virus neuraminidase.  Peramivir inhibits the neuraminidase activity of several strains of influenza A and B viruses, including H1N1 influenza A (swine influenza). 6. Zebra -Ceftolozane and Tazobactam Injection Company: Cubist Pharmaceuticals, Inc. Approved indication: Intraabdominal Infection, Urinary Tract Infection  Ceftolozane and Tazobactam is a cephalosporin and beta-lactamase inhibitor combination for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Molecular mechanism  Ceftolozane-Inhibit the cell wall synthesis.  Tazobactum-Beta-lactamase inhibitor.
  • 8. 4/16/20158 7.Lynparza-Olaparib Capsules Company: AstraZeneca Approved indication: Ovarian Cancer Mechanism of Action:  Poly adenosine 5’-diphospho ribose polymerase (PARP) family inhibitor PARP-1 PARP- 2 PARP-3. 8. Viekira Pak -Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir Tablets Company: AbbVie Inc. Approved indication: Chronic Hepatitis C  Viekira Pak for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.
  • 9. 4/16/20159 Mechanism of action Ombitasvir - NS5A inhibitor with potent pangenotypic picomolar antiviral activity Paritaprevir - Inhibitor of the NS3/4A serine protease Ritonavir – Potent inhibitor of CYP3A4 enzymes Dasabuvir - Nonnucleoside NS5B polymerase inhibitor and also used for pharmacologic booster paritaprevir 9. Soolantra -Ivermectin Cream Company: Galderma Laboratories, L.P. Approved indication: Acne Rosacea  Lvermectin is a topical antiparasitic with anti-inflammatory properties for the treatment of rosacea potentially caused by the microscopic skin mite Demodex folliculorum. Molecular mechanism  Anthelmintic drug- Inhibiting neuronal activity and muscular contractility in arthropods and nematodes  By activating glutamate-gated chloride channels (GluClRs) at nanomolar concentrations
  • 10. 4/16/201510 10.Xtoro -Finafloxacin Otic Suspension Company: Alcon Laboratories, Inc. Approved indication : Otitis Externa Finafloxacin Otic suspension is a fluoroquinolone antimicrobial for the treatment of acute otitis externa, commonly known as swimmer’s ear. Molecular mechanism Quinolones-Inhibit the enzyme bacterial DNA gyrase. 11.Signifor LAR -Pasireotide for Injectable Suspension Company: Novartis Approved indication: Acromegaly Pasireotide is a long acting a somatostatin analog formulation for the treatment of patients with acromegaly.
  • 11. 4/16/201511 Molecular mechanism 1. Pasireotide activates somatostatin receptors, exhibiting a much higher binding affinity for Somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing's disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
  • 12. 12.Gardasil 9 -Human papillomavirus 9-valent vaccine, recombinant Injection Company: Merck & Co., Inc. Approved indication: Human Papillomavirus Prophylaxis Human papillomavirus 9-valent vaccine, recombinant) is a 9-valent HPV vaccine for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 13.Blincyto -Blinatumomab Injection Company: Amgen Inc. Approved indication: Acute Lymphoblastic Leukemia Blinatumomab is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 4/16/201512
  • 13. 4/16/201513 Molecular mechanism  A molecule of Blinatumomab combines two binding sites:  CD3 site for T cells and CD19 site for the target B cells.  CD3 is part of the T cell receptor.  The drug works by linking these two cell types activating the T cell to exert cytotoxic activity on the target cell. 14.Kitabis Pak -Tobramycin Inhalation Solution Company: PulmoFlow, Inc. Approved indication: Cystic Fibrosis Tobramycin is an aminoglycoside inhalation solution co- packaged with a PARI LC PLUS® Reusable Nebulizer for the management of cystic fibrosis.
  • 14. 4/16/201514 Molecular mechanism Tobramycin binding to a site on the bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, mRNA cannot be translated into protein and cell death . 15.Onexton-Benzoyl peroxide and Clindamycin phosphate Gel Company: Valeant Pharmaceuticals International, Inc. Approved indication: Acne Benzoyl peroxide and Clindamycin phosphate is an antimicrobial and lincosamide antibacterial combination for the once-daily topical treatment of acne vulgaris
  • 15. 4/16/201515 Molecular mechanism Clindamycin: It is a lincosamide antibacterial. Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bacteriocidal and keratolytic effects, but the precise mechanism of action is unknown. 16.Hysingla ER-Hydrocodone bitartrate Extended- Release Tablets Company: Purdue Pharma L.P. Approved indication: Chronic Pain Hydrocodone is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.
  • 16. 4/16/201516 Molecular mechanism  As a narcotic, Hydrocodone relieves pain by binding to Opioid receptors in the CNS.  It acts primarily on μ-opioid receptors, with about six times lesser affinity to δ-opioid receptors.  In blood, 20–50% of hydrocodone is bound to protein. 17.Lemtrada-Alemtuzumab Injection Company: Genzyme Approved indication: Multiple Sclerosis  Alemtuzumab is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS). Molecular mechanism  Alemtuzumab is a humanized mAb, which targets the surface molecule CD52 on all T cell populations and other cellular components of the immune system such as thymocytes, B cells, and monocytes.  Alemtuzumab, which is administered intravenously, depletes T as well as B lymphocyte populations for extended periods. Adverse effects in MS patients such as thyroid disorders and idiopathic thrombocytopenic purpura.
  • 17. 4/16/201517 18.Xigduo XR -Dapagliflozin and Metformin hydrochloride Extended-Release Tablets Company: AstraZeneca Approved indication: Diabetes Type 2  Xigduo XR (Dapagliflozin and Metformin hydrochloride)  It is a once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.
  • 18. 4/16/201518 Molecular mechanism Dapagliflozin –  Inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2)  which are responsible for at least 90% of the glucose reabsorption in the kidney.  Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. Metformin  Metformin decreases hyperglycemia primarily by suppressing glucose production by the liver (hepatic gluconeogenesis). 19.Trumenba -meningococcal group B vaccine Company: Pfizer Inc. Approved indication: Meningococcal Meningitis Prophylaxis  Trumenba (Meningococcal group B vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in adolescents and young adults.